In Figure 3, the mentioned above cutoffs (≥250 eosinophils and ≥9.3 PTGDR2 expression) determine four quadrants (Q1, Q2, Q3, Q4); these patients were located in the Q2 quadrant and were distributed into the following groups: Rhinitis (4 patients), asthma with polyposis (3 patients, including one with AERD), asthma without polyposis (3 patients) and polyposis without asthma (one patient). Here, PTGDR2 is linked to polyposis.